1. Dept. & Center for Biotechnology Research, Semnan University of Medical Sciences, Semnan, Iran. Students Research Committe, Semnan University of Medical Sciences, Semnan, Iran. 2. Dept. & Center for Biotechnology Research, Semnan University of Medical Sciences, Semnan, Iran.
Abstract
Introduction
Passive immunization provides immune-mediated protection via delivery of antibodies or antibody-encoding genes and offers an immediate action. protein-based therapeutic approaches bear limitations such as the high cost of production and storage. dna-based therapeutics are hindered by the risk of genomic integration and immunogenicity of viral vectors. as an attractive alternative to the traditional approaches, exogenous mrna encoding antibody can quickly direct high levels of in vivo expression of functional antibody. this review presents the current state of mrna technology in the field of antibody production for passive vaccination against pathogens, as well as discussing the future perspectives and challenges of this alternative approach.
Methods
This is a review essay.
Results
Recent reports have demonstrated that injectable antibody-encoding mrna can use for in vivo production of protective antibodies against infectious agents and toxins. the in vivo half-life of mrnas can be regulated by applying various modifications and delivery methods. mrna therapeutics offer a safe, simple and cost-effective alternative to dna-based approaches and recombinant antibody therapies. flexibility of mrna technology provides the possibility of expression of different antibody formats against diverse biological threats.
Conclusion
These achievements suggest the utility of formulated mrna as a potential novel technology for passive vaccination.
